Galderma, the leading company solely dedicated to advancing the future of dermatology, today premiered the positive phase III results from the OLYMPIA 2 trial evaluating the efficacy, safety, pharmacokinetics and immunogenicity of nemolizumab compared with placebo in adult patients with prurigo nodularis.
AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab s Significant Impact on Prurigo Nodularis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Extensive updates from broad and innovative portfolio also to be presented The 2023 American Academy of Dermatology (AAD) Annual Meeting will see the data premiere of the phase III OLYMPIA 2
New pivotal study data demonstrating the safety and effectiveness of Sculptra, the only U.S. FDA-approved PLLA biostimulator, in the correction of cheek.